Detalhe da pesquisa
1.
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Br J Cancer
; 130(8): 1377-1387, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396173
2.
Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue.
Clin Proteomics
; 20(1): 47, 2023 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880622
3.
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Blood
; 138(18): 1705-1720, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077955
4.
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Br J Cancer
; 119(10): 1233-1243, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30385821
5.
SRC-induced disassembly of adherens junctions requires localized phosphorylation and degradation of the rac activator tiam1.
Mol Cell
; 33(5): 639-53, 2009 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-19285946
6.
Infraoccluded Upper Deciduous Second Molars Leading to Caries in the Permanent Dentition.
Dent Update
; 42(5): 485-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26964450
7.
Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma.
Front Toxicol
; 5: 1200650, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441092
8.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 64, 2023 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543694
9.
The Rac activator STEF (Tiam2) regulates cell migration by microtubule-mediated focal adhesion disassembly.
EMBO Rep
; 11(4): 292-8, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20224579
10.
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5ß1: part 1.
Bioorg Med Chem Lett
; 22(12): 4111-6, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22575869
11.
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5ß1: part 2.
Bioorg Med Chem Lett
; 22(12): 4117-21, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22572578
12.
Delivering Cognitive Stimulation Therapy (CST) Virtually: Developing and Field-Testing a New Framework.
Clin Interv Aging
; 17: 97-116, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173425
13.
The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer.
Respiration
; 81(2): 89-104, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21311210
14.
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
J Clin Oncol
; 39(3): 190-201, 2021 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33326257
15.
The pathogenesis of mesothelioma is driven by a dysregulated translatome.
Nat Commun
; 12(1): 4920, 2021 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34389715
16.
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Mol Cancer Ther
; 20(2): 238-249, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33273059
17.
An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
Cancer Res
; 79(7): 1480-1492, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30674531
18.
STEF/TIAM2-mediated Rac1 activity at the nuclear envelope regulates the perinuclear actin cap.
Nat Commun
; 9(1): 2124, 2018 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29844364
19.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 76, 2023 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726304
20.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
NPJ Breast Cancer
; 9(1): 69, 2023 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37596288